Genezen Appoints Vice President of Quality Assurance and Regulatory Affairs

Scroll Down

Genezen Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has appointed Natasha Rivas as Vice President of Quality Assurance and Regulatory Affairs.

She will be responsible for the design, implementation and iteration of the quality systems and processes that meet our customers’ evolving needs and ensure delivery of safe and effective drug products.

Natasha brings more than 20 years of experience in the pharmaceutical and medical device industry, previously holding roles in quality control, assurance and regulatory affairs at Abbott, Hospira, Vetter Pharma and SCA Pharmaceuticals. She has an exemplary track record in building teams and quality systems to support drug development and clinical and commercial operations in the pharmaceutical industry.

Commenting on her appointment, Ms. Rivas said: “I’m excited to join Genezen at a pivotal moment in the company’s growth as the company develops new infrastructure and adds expertise on the way to becoming a leading lentiviral and retroviral vector CDMO.

Genezen has recently appointed Ray Kaczmarek as CEO and Brok Weichbrodt as Vice President of Operations following news that the company has broken ground on a new multiphase master plan for a 75,000+ square foot cGMP-compliant Lentiviral vector production facility.

“Cell and gene therapy is an exciting therapeutic frontier to be in and I am proud to be a part of the team that will help bring high quality products and innovative solutions to not only treat but potentially cure patients.”

Natasha is a Certified Quality Auditor through ASQ and an active member of the Parenteral Drug Association (PDA).

Commenting on Natasha’s appointment Ray Kaczmarek added: “We are thrilled to add Natasha to our team at Genezen. Her credentials in developing and optimizing robust quality systems will be integral in our mission to make high-quality vector production accessible for innovative drug developers.”

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more